A carregar...
Carfilzomib for relapsed and refractory multiple myeloma
Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory disease. Several new therapeutics have been developed in the last few years, including carfilzomib, a second-generation proteasome inh...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6450182/ https://ncbi.nlm.nih.gov/pubmed/31037034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S150653 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|